Research progress of biomarkers in diagnosis and therapy of colorectal cancer

国际生物医学工程杂志 Pub Date : 2019-12-28 DOI:10.3760/CMA.J.ISSN.1673-4181.2019.06.013

Liang Tang

{"title":"Research progress of biomarkers in diagnosis and therapy of colorectal cancer","authors":"Liang Tang","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.06.013","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) is one of the most common human malignant diseases, the cumulative result of genetic and epigenetic mutations, and its mortality rate is second only to that of lung cancer. Most patients with CRC have developed to middle to advanced stage when symptoms appear, and the treatment effects of surgery and chemotherapy are usually not satisfactory. With the emergence of targeted drugs in recent years, individualized treatment of colorectal cancer has gradually become a trend. With the development of colorectal cancer research, more and more molecular markers of colorectal cancer have been continuously discovered, and its impact on tumorigenesis, development and treatment has gradually received more attention. The application of molecular markers in the screening of colorectal cancer can help the early detection and diagnosis. Detection of molecular markers before individualized treatment can optimize the treatment plan and prompt the patient's prognosis. In this paper, the most recent findings of molecular markers with promising clinical application were summarized, in order to provide reference for the early diagnosis and treatment of colorectal cancer. \n \n \nKey words: \nColorectal cancer; Biomarker; CpG island methylator phenotype; Oncogene; Tumor suppressor gene","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际生物医学工程杂志","FirstCategoryId":"1087","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.06.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) is one of the most common human malignant diseases, the cumulative result of genetic and epigenetic mutations, and its mortality rate is second only to that of lung cancer. Most patients with CRC have developed to middle to advanced stage when symptoms appear, and the treatment effects of surgery and chemotherapy are usually not satisfactory. With the emergence of targeted drugs in recent years, individualized treatment of colorectal cancer has gradually become a trend. With the development of colorectal cancer research, more and more molecular markers of colorectal cancer have been continuously discovered, and its impact on tumorigenesis, development and treatment has gradually received more attention. The application of molecular markers in the screening of colorectal cancer can help the early detection and diagnosis. Detection of molecular markers before individualized treatment can optimize the treatment plan and prompt the patient's prognosis. In this paper, the most recent findings of molecular markers with promising clinical application were summarized, in order to provide reference for the early diagnosis and treatment of colorectal cancer. Key words: Colorectal cancer; Biomarker; CpG island methylator phenotype; Oncogene; Tumor suppressor gene

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症生物标志物在结直肠癌诊断和治疗中的研究进展

癌症是人类最常见的恶性疾病之一，是遗传和表观遗传突变的累积结果，其死亡率仅次于癌症。大多数CRC患者在出现症状时已发展到中晚期，手术和化疗的治疗效果通常不令人满意。随着近年来靶向药物的出现，癌症个体化治疗逐渐成为一种趋势。随着癌症研究的发展，越来越多的癌症分子标志物被不断发现，其对肿瘤发生、发展和治疗的影响也逐渐受到人们的重视。分子标记物在癌症筛查中的应用有助于结直肠癌的早期检测和诊断。个体化治疗前检测分子标志物可以优化治疗计划，提示患者预后。本文综述了具有临床应用前景的分子标志物的最新发现，为癌症的早期诊断和治疗提供参考。关键词：结直肠癌癌症；生物标志物；CpG岛甲基化子表型；肿瘤基因；肿瘤抑制基因

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

国际生物医学工程杂志

自引率

0.00%

发文量

1974